Home > Press > Abraxis BioScience Announces Date for 2009 Third Quarter Financial Results and Investor Conference Call
Abraxis BioScience, Inc. (NASDAQ:ABII), an integrated, global biopharmaceutical company, today announced it will release its 2009 third quarter financial results before the market opens on Thursday, November 5, 2009. The company also said that senior management will host an investor conference call the same day at 8:30 a.m. PT/11:30 a.m. ET to review the company's financial results.
Abraxis BioScience Announces Date for 2009 Third Quarter Financial Results and Investor Conference Call
Los Angeles, CA | Posted on October 16th, 2009
The conference call will be available to interested parties through a live audio webcast at www.abraxisbio.com and www.earnings.com. The call will also be archived and accessible at both sites for six months.
About Abraxis BioScience
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE®), which is based on the company's proprietary tumor targeting technology known as the nab® platform. The first FDA approved product to use this nab platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 38 countries. The company continues to expand the nab platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII.
For more information, please click here
Investors and Media Inquiries:
Abraxis BioScience, Inc.
Copyright © Abraxis BioScience
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
News and information
Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013
NanoInk, Inc. Assets To Be Sold May 18th, 2013
Beautiful "flowers" self-assemble in a beaker: Elaborate nanostructures blossom from a chemical reaction perfected at Harvard May 17th, 2013
Scientists capture first direct proof of Hofstadter butterfly effect May 17th, 2013
Nanobiotix Revenue for the 1st quarter of 2013 May 15th, 2013
Harris & Harris Group Reports Financial Statements as of March 31, 2013 May 10th, 2013
Arrowhead Reports Fiscal 2013 Second Quarter Financial Results - Conference Call Today at 4:30 p.m. Eastern Time May 9th, 2013
Arrowhead to Report Fiscal 2013 Second Quarter Financial Results - Conference Call Scheduled for Thursday, May 9, 2013 May 2nd, 2013
Lifeboat publishes its first book: The Lifeboat Foundation has published its first book, "The Human Race to the Future: What Could Happen -- and What to Do" May 14th, 2013
Combining Nanowires and Memristors Could Lead to Brain-like Computing April 4th, 2013
Jaan Tallinn named 2012 Lifeboat Foundation Guardian Award Winner December 13th, 2012
Technology making a splash: Nanotechnology works on such a small scale it allows scientists to harness the precision of nature – the benefits are almost limitless. But, asks Penny Sarchet, what are the risks? April 1st, 2012